Zobrazeno 61 - 70
of 328
pro vyhledávání: '"Auro Viswabandya"'
Autor:
Auro Viswabandya, Wilson Lam, Maria Queralt Salas, Eshetu G. Atenafu, Rajat Kumar, Shruti Prem, David Loach, Zeyad Al-Shaibani, Jeffrey H. Lipton, Arjun Datt Law, Dennis Dong Hwan Kim, Fotios V. Michelis, Jonas Mattsson
Publikováno v:
European Journal of Haematology. 103:510-518
Objectives We aimed to study the efficacy of reduced intensity conditioning (RIC) allo-HSCT combined with anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis in AML. Methods One h
Autor:
Rajat Kumar, Fotios V. Michelis, Elizabeth Shin, Jeffrey H. Lipton, Auro Viswabandya, Dennis Dong Hwan Kim, Jonas Mattsson, Arjun Datt Law, Wilson Lam, Roman M Shapiro, Hans A. Messner
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:1761-1769
The Centre for International Blood and Marrow Transplant Registry (CIBMTR) score has been shown to be prognostic for overall survival (OS) and nonrelapse mortality (NRM) but has been shown in several single-center studies to classify a large proporti
Autor:
Igor Novitzky‐Basso, Mats Remberger, Carol Chen, Cynthia Ellison, Ivan Pasic, Wilson Lam, Arjun Law, Armin Gerbitz, Auro Viswabandya, Jeffrey H. Lipton, Dennis D. Kim, Rajat Kumar, Fotios V. Michelis, Jonas Mattsson
Publikováno v:
European journal of haematologyREFERENCES. 108(4)
In donor selection for allogeneic stem cell transplant, several factors are considered for potential impact on transplant outcome. Previous publications suggested single HLA-mismatched unrelated donors (MMUD) may be equivalent to 10/10 matched unrela
Autor:
Maria Queralt Salas, Ivan Pasic, Mats Remberger, Igor Novitzky-Basso, Arjun Datt Law, Wilson Lam, Carol Chen, Dennis (Dong Hwan) Kim, Fotios V. Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey Howard Lipton, Rajat Kumar, Jonas Mattsson
Publikováno v:
Transplantation and cellular therapy. 28(5)
The implementation of dual T-cell depletion comprising 4.5 mg/kg of antithymocyte globulin (ATG), post-transplantation cyclophosphamide, and cyclosporine A for reduced-intensity allogeneic hematopoietic cell transplantation (HCT) independent of donor
Autor:
Jeffrey H. Lipton, Fotios V. Michelis, Wilson Lam, Carol Chen, Auro Viswabandya, Zeyad Al-Shaibani, Arjun Datt Law, Rajat Kumar, Armin Gerbitz, Ivan Pasic, Swe Mar Linn, Dennis Dong Hwan Kim, Jonas Mattsson, Ram V Nampoothiri
Publikováno v:
Hematology/Oncology and Stem Cell Therapy.
BACKGROUND Allogeneic hematopoietic stem cell transplantation (allo-HCT) is currently the only curative treatment for patients with chronic lymphocytic leukemia (CLL). METHODS We analyzed the outcomes of 93 patients (median age: 52 years) who underwe
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 28(8)
Introduction Patients admitted for allogeneic hematopoietic stem cell transplantation (allo-HSCT) are discharged with multiple new medications. At our institution, a new patient Self Medication Program (SMP) was implemented on the allo-HSCT units. An
Autor:
María Queralt Salas, Eshetu G. Atenafu, Eshrak Al-Shaibani, Ora Bascom, Leeann Wilson, Ivan Pasic, Arjun Datt Law, Wilson Lam, Dennis D Kim, Armin Gerbitz, Auro Viswabandya, Jeffrey H Lipton, Fotios V Michelis, Jonas Mattsson, Shabbir MH Alibhai, Rajat Kumar
Publikováno v:
Transplantation and Cellular Therapy. 28:S439-S440
Autor:
Rajat Kumar, Auro Viswabandya, Fotios V. Michelis, Jeffrey H. Lipton, Maria Queralt Salas, Armin Gerbitz, Dennis Dong Hwan Kim, Jonas Mattsson, Eshetu G. Atenafu, Carol Chen, Ivan Pasic, Wilson Lam, Arjun Datt Law
Publikováno v:
Leukemialymphoma. 62(14)
This study compares the outcomes before and after reducing the ATG dose from 4.5 to 2 mg/kg, in a combination of PTCy and CsA for GVHD prevention, in 250 patients treated with HLA matched RIC PB-alloHCT (70% received 4.5 mg/kg and 30% received 2 mg/k
Autor:
Arjun Datt Law, Fotios V. Michelis, Armin Gerbitz, Maria Queralt Salas, Jeffrey H. Lipton, Ivan Pasic, Shahid Husain, Igor Novitzky Basso, Rajat Kumar, Wilson Lam, Abel Santos Carreira, M Remberger, Dennis Dong Hwan Kim, Jonas Mattsson, Auro Viswabandya
Publikováno v:
Transplantation and cellular therapy. 28(1)
This study investigated the single-center incidence and risk factors for bloodstream infections (BSIs) in 651 adults who underwent allogeneic hematopoietic cell transplantation (alloHCT) between 2015 and 2019 and explored the impact of these BSIs on
Autor:
Rajat Kumar, Dennis Dong Hwan Kim, Jonas Mattsson, David Loach, Arjun Datt Law, Zeyad Al-Shaibani, Carol Chen, Wilson Lam, Fotios V. Michelis, Jeffrey H. Lipton, Auro Viswabandya, Ram V Nampoothiri
Publikováno v:
Hematology/Oncology and Stem Cell Therapy.
Background/Objective Existing literature on allogeneic hematopoietic stem cell transplantation (allo-HSCT) in therapy-related acute myeloid leukemia (t-AML) is confounded by the inclusion of patients with secondary AML and t-MDS. We aim to report our